ADViRNA is a specialized Contract Research Organization focused on oligonucleotide-based therapeutics such as siRNAs and antisense oligonucleotides (ASOs). They provide an end-to-end workflow that includes design, synthesis (with chemical modifications and conjugations), high-throughput screening, biodistribution studies, and reagent supply. Their in-house capabilities cover a wide range of molecular and cellular assays, including qPCR, ELISA, Western blot, flow cytometry, cytotoxicity and immune assays, as well as their proprietary HYBRID-ON™ platform for detecting chemically modified oligonucleotides in biological samples. Equipped with automated liquid handlers, oligonucleotide synthesizers, LC-MS systems, and advanced plate readers, ADViRNA tailors each project to the client’s biological model and research goals, providing customized, data-driven support for oligo discovery and validation across diverse disease areas.